Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Mol Neurobiol ; 58(9): 4716-4726, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34169444

ABSTRACT

First-line therapy with interferon beta (IFN-ß), involved in gene expression modulation in immune response, is widely used for multiple sclerosis. However, 30-50% of patients do not respond optimally. Variants in CBLB, CTSS, GRIA3, OAS1 and TNFRSF10A genes have been proposed to contribute to the variation in the individual response. The purpose of this study was to evaluate the influence of gene polymorphisms on the IFN-ß response in relapsing-remitting multiple sclerosis (RRMS) patients. CBLB (rs12487066), GRIA3 (rs12557782), CTSS (rs1136774), OAS1 (rs10774671) and TNFRSF10A (rs20576) polymorphisms were analysed by Taqman in 137 RRMS patients. Response to IFN-ß and change in the Expanded Disability Status Scale (EDSS) after 24 months were evaluated using multivariable logistic regression analysis. Carriers of at least one copy of the C allele of CTSS-rs1136774 had a better response to IFN-ß (p = 0.0423; OR = 2.94; CI95% = 1.03, 8.40). Carriers of TT genotype of TNFRSF10A-rs20576 had a higher probability of maintaining their EDSS stable after 24 months of IFN-ß treatment (p = 0.0251; OR = 5.71; CI95% = 1.39, 31.75). No influence of CBLB (rs12487066), OAS1 (rs10774671) and GRIA3 (rs12557782) gene polymorphisms in the variation of the individual response to IFN-ß was shown. Our results suggest that the TNFRSF10A-rs20576 and CTSS-rs1136774 gene polymorphisms influence the response to IFN-ß after 24 months, while the CBLB (rs12487066), OAS1 (rs10774671) or GRIA3 (rs12557782) gene polymorphisms had no effect on the variation of the individual response to IFN-ß.


Subject(s)
Interferon-beta/therapeutic use , Multiple Sclerosis/drug therapy , Polymorphism, Single Nucleotide , 2',5'-Oligoadenylate Synthetase/genetics , Adaptor Proteins, Signal Transducing/genetics , Adolescent , Adult , Alleles , Cathepsins/genetics , Female , Genotype , Humans , Male , Multiple Sclerosis/genetics , Pharmacogenetics , Proto-Oncogene Proteins c-cbl/genetics , Receptors, AMPA/genetics , Receptors, TNF-Related Apoptosis-Inducing Ligand/genetics , Young Adult
2.
Pharmacogenomics ; 16(10): 1189-222, 2015.
Article in English | MEDLINE | ID: mdl-26237292

ABSTRACT

Colorectal cancer is a tumor with increasing incidence which represents one of the first leading causes of death worldwide. Gene alterations described for colorectal cancer include genome instability (microsatellite and chromosomal instability), CpG islands methylator phenotype, microRNA, histone modification, protein biomarkers, gene mutations (RAS, BRAF, PI3K, TP53, PTEN) and polymorphisms (APC, CTNNB1, DCC). In this article, biomarkers with prognostic value commonly found in colorectal cancer will be reviewed.


Subject(s)
Biomarkers, Tumor/genetics , Colorectal Neoplasms/genetics , CpG Islands/genetics , DNA Methylation/genetics , Genomic Instability/genetics , Humans , MicroRNAs/genetics , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL